Laryngeal Carcinoma: Staging and Management

Anatomy and Subsite Classification

• Supraglottis: epiglottis, aryepiglottic folds, arytenoids, false (ventricular) folds
• Glottis: true vocal folds (TVFs), anterior and posterior commissures (extends 1 cm below TVF level)
• Subglottis: below the glottis to the inferior border of the cricoid cartilage

~95% of laryngeal cancers are squamous cell carcinomas (SCC). Glottic SCC is the most common subsite (~65%), followed by supraglottic (~30%), then subglottic (<5%).

TNM Classification (AJCC 8th Edition / UICC 9th Edition)

Primary Tumor (T) - by Subsite

Supraglottic

Glottic

Subglottic

Regional Lymph Nodes (N) - AJCC 8th Ed. (incorporates extranodal extension)

Distant Metastasis (M)

Overall Stage Grouping

Nodal Metastasis Risk by Subsite

• Glottic cancer has the lowest nodal risk due to sparse lymphatics at the TVF level.
• Supraglottic cancer drains bilaterally to levels II-IV; therefore bilateral neck management is required even in N0 disease.

Management by Stage

Stage 0 (Tis - Carcinoma In Situ)

• Transoral laser microsurgery (TLM) with CO2 laser - treatment of choice
• Superficial cordectomy (endoscopic)
• Radiation therapy is an option but generally reserved to avoid depleting future RT options
• No neck dissection required

Stage I (T1N0M0)

Glottic T1

• Radiation therapy (RT) with curative intent: ~5,000-6,300 cGy delivers local control rates of 85-95% for T1a. Voice quality outcomes are excellent.
• Transoral laser microsurgery (TLM): local control comparable to RT for T1a; preferred when voice quality preservation is paramount. Allows pathologic margin assessment.
• Both modalities yield equivalent survival; RT preferred by many centers for voice quality; TLM preserves RT for potential future use.
• Neck: No treatment of N0 neck necessary for T1-T2 glottic cancer (occult nodal metastasis <5%).

Supraglottic T1

• RT or TLM are both appropriate
• Bilateral neck treatment is recommended (elective bilateral levels II-IV) even for N0 disease due to 10-29% occult nodal metastasis rate

Stage II (T2N0M0)

Glottic T2

• RT with curative intent: local control ~65-80% for T2; impaired cord mobility (T2 with fixation tendency) has lower control rates
• TLM for select T2 lesions (no subglottic extension, accessible)
• Open partial laryngectomy (vertical hemilaryngectomy) for select T2 glottic lesions - less commonly used now
• Neck: still low nodal risk; N0 neck generally does not require elective treatment

Supraglottic T2

• RT or TLM with bilateral elective neck treatment
• Supraglottic laryngectomy (open) is an option for T1-T2 with normal vocal fold mobility, tumor limited to supraglottis, adequate pulmonary reserve
  • Contraindicated: vocal fold fixation, interarytenoid involvement, poor pulmonary status, thyroid cartilage invasion

Stage III (T3N0M0 or T1-3, N1, M0)

Options:

1. Concurrent chemoradiotherapy (CRT) - cisplatin-based CRT with RT is the standard organ-preservation approach. Based on the landmark RTOG 91-11 trial showing superiority of concurrent CRT over induction chemotherapy followed by RT or RT alone for larynx preservation.
2. Induction chemotherapy (TPF: docetaxel, cisplatin, 5-FU) followed by RT - used in select patients to test chemosensitivity; if complete response, definitive RT follows.
3. Total laryngectomy + postoperative RT (with or without chemotherapy if high-risk features: positive margins, ENE) - indicated when organ preservation is not feasible (e.g., poor laryngeal function, cartilage invasion, pre-existing aspiration).
4. Transoral or open partial laryngectomy (supracricoid laryngectomy) in highly selected T3 patients with limited thyroid cartilage involvement and good pulmonary function.
   • Reconstructed with cricohyoidopexy (CHP) or cricohyoidoepiglottopexy (CHEP) if epiglottis is spared.

Neck (N1):

• Comprehensive neck dissection or definitive RT/CRT field inclusion
• Post-CRT: PET/CT at 12 weeks post-treatment - if complete response, planned neck dissection is NOT necessary (level I evidence)

Stage IVA (T4a with N0-1, or T1-T4a with N2)

• Total laryngectomy is the preferred primary treatment for T4a (cartilage invasion through and through, extralaryngeal spread)
• Followed by postoperative RT (60 Gy) or postoperative CRT (cisplatin) if high-risk features present (positive/close margins, ENE, perineural invasion, lymphovascular invasion, multiple positive nodes)
• Organ preservation (CRT) can still be considered in select T4a patients without gross cartilage invasion; however outcomes are generally inferior
• Tracheoesophageal voice prosthesis (TEP) placed at time of laryngectomy for voice rehabilitation
• Bilateral neck management required

Stage IVB (T4b or N3)

• T4b disease (carotid encasement, prevertebral fascia, mediastinal invasion) is generally unresectable
• Treatment: Definitive CRT (palliative intent or aggressive curative intent in carefully selected patients)
• N3 disease: aggressive CRT ± planned neck dissection
• Cetuximab (EGFR inhibitor) + RT may be used in patients unfit for cisplatin

Stage IVC (M1 - Distant Metastasis)

• Palliative systemic therapy is the mainstay
• First-line: Pembrolizumab (PD-1 inhibitor) monotherapy if PD-L1 CPS ≥1, or pembrolizumab + platinum/5-FU (based on KEYNOTE-048)
• Alternatively: cetuximab + platinum + 5-FU (EXTREME regimen)
• RT for symptom control (airway, pain)
• Tracheotomy/airway management as needed
• Multidisciplinary palliative care involvement

Summary Table

Key Principles

1. Glottic cancer presents early (hoarseness) and carries low nodal risk - best prognosis among subsites.
2. Supraglottic cancer presents late and carries high bilateral nodal risk - always treat the neck bilaterally.
3. Subglottic cancer is rare, aggressive, and has higher risk for level VI and paratracheal nodal spread.
4. Larynx preservation via CRT (RTOG 91-11 protocol) is the standard for most stage III-IVA disease; total laryngectomy is reserved for failed preservation, T4a with cartilage invasion, or poor laryngeal function.
5. Post-treatment PET/CT at 12 weeks after CRT can guide neck dissection decisions - complete metabolic response avoids planned ND.
6. Imaging: CT neck with contrast is the workhorse for staging. MRI offers superior soft-tissue detail. PET/CT is standard for distant staging and post-treatment response assessment.

Organ Preservation vs. Total Laryngectomy: Outcome Comparison

Core Comparison Table

Functional Outcomes

Quality of Life (QoL)

Perioperative / Treatment-Related Morbidity

Stage-Specific Summary: Which Strategy Wins?

Key Landmark Trials Referenced